https://wohlfruchter.com/cases/elanco-animal-health/ Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com. Why is there an investigation? On June 27, 2024, Elanco announced that the U.S. label for Zenrelia will carry a boxed warning to highlight safety concerns. Elanco further advised that it expected this warning to slow adoption of Zenrelia in the U.S. and initially limit the number of expected treatment days by approximately 25%. Elanco indicated that it pla ...

Loading... Elanco Animal Health Incorporated ELAN stock is tumbling as the company released updates to the expected FDA approval timelines for Zenrelia and Credelio Quattro. For the minor technical section for labeling, earlier this week, the company aligned with the FDA on the language and expects to receive the completion letter by mid-July. "However, we expect the U.S. label will include a boxed warning on safety based on the outcome of a trial with unvaccinated dogs dosed at 3x the label dose," said Bob ...

Major technical sections complete for Zenrelia, with FDA final approval on track for late in third quarter of 2024; updates on differentiation and safety Final FDA approval for Credelio Quattro now expected in the fourth quarter of 2024 First Zenrelia approval received in Brazil 2024 Innovation sales guidance increased GREENFIELD, Ind., June 27, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to the expected U.S. Food and Drug Administration (FDA) approval timelin ...

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Most Powerful Force Impacting Stock Prices Elanco Animal Health Incorporated (ELAN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

GREENFIELD, Ind., June 6, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 45th Annual Global Healthcare Conference, June 11-12, 2024. Jeff Simmons, President and CEO, will participate in a fireside chat on Tuesday, June 11 at 2:40 p.m. ET. A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELA ...

Food and Drug Administration confirms Bovaer meets safety and efficacy requirements Elanco expects product launch and added carbon credit value to producers beginning in the third quarter Elanco announces agreement with dsm-firmenich to expand distribution of Bovaer across North America, adding both the Canada and Mexico markets GREENFIELD, Ind., May 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its comprehen ...

Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jeff Simmons - President, Chief Executive Officer Todd Young - Executive Vice President, Chief Financial Officer Katy Grissom - Head of Investor Relations Conference Call Participants Jon Block - Stifel Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Mike DiFiore - Evercore ISI Ekaterina Knyazkova - JP Morgan Brandon Vazquez - William Blair Nathan Rich - Goldman Sachs Dav ...

Elanco Animal Health Incorporated (ELAN) reported $1.21 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 4.1%. EPS of $0.34 for the same period compares to $0.45 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.17 billion, representing a surprise of +2.69%. The company delivered an EPS surprise of +30.77%, with the consensus EPS estimate being $0.26.While investors closely watch year-over-year changes in headline numbers -- revenue a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _______ COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) (State or other jurisdicti ...

+$10M of cash from inventory, while building approx. $15M of inventory for launches Note: Numbers may not add due to rounding. 1Net debt is a non-GAAP measure calculated as gross debt less cash and cash equivalents on our balance sheet. Gross debt is the sum of the current portion of long-term debt and long-term debt and excludes unamortized debt issuance costs. 2Net leverage ratio is calculated as net debt divided by trailing 12 month adjusted EBITDA. This calculation does not include Term Loan B covenant- ...